Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × capmatinib × 1 year × Clear all

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-02-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05110196 2025-12-03

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04926831 2025-10-16

Geometry-N

Phase 2 Terminated

4 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04677595 2025-06-24

GeoMETry-C

Phase 2 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Managed Access Programs for INC280, Capmatinib

METalmark

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Geometry-N

Special Drug Use-results Surveillance of Tabrecta Tablets

GeoMETry-C

GeoMETry-III